OPKNot HalalF
Unlock full report, free

Is OPKO Health (OPK) Stock Halal?

Compliance Status

Not Halal

Screened on Nov 7, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is OPKO Health, Inc. (OPK) halal? Not Halal. Based on AAOIFI screening, OPKO Health, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates OPKO Health, Inc. (OPK) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 7, 2026. Source: https://halalscreener.app/en/stock/OPK

Business activity

What the company sells is permissible.

Passed

Company debt

Over the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

36.6% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding OPK

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Share this verdict

A receipt-style image with the math on it, so whoever you send it to can check it.

OPKO Health, Inc.

OPK

OPKO Health, Inc.

NASDAQHealthcareUS

$1.75

-1.13%

Market Cap: 1.3B

Get an email if OPK's halal status changes

We re-screen OPKO Health, Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About OPKO Health, Inc.

OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

Sector: Healthcare · Industry: Medical - Diagnostics & Research

Why this does not pass

  • Interest-bearing debt is 36.6% of market cap, over the 30% AAOIFI limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Nov 7, 2026
AI Compliance InsightProSee plans
Revenue BreakdownProSee plans

Compliance History

  1. Not Halalnow

    since Nov 2026

  2. Doubtful

    until the change above

  3. Not Halal

    until the change above

  4. Doubtful

    until the change above

  5. Not Halal

    until the change above

  6. Doubtful

    until the change above

  7. Not Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q3 2026Data source: EDGAR
Free · No credit card required

Know the day OPK's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is OPKO Health, Inc. (OPK) halal to invest in?
OPKO Health, Inc. (OPK) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did OPKO Health, Inc. get a F compliance rating?
OPKO Health, Inc. (OPK) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 36.6% (limit 30%); interest-bearing deposits close to the 30% limit; prohibited income well clear of the 5% limit. The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change OPKO Health, Inc.'s Shariah verdict?
OPKO Health, Inc.'s verdict is recalculated at every re-screen, including the one that follows each new quarterly or annual report. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is OPKO Health, Inc. re-screened for Shariah compliance?
OPKO Health, Inc. (OPK) is screened from the latest financial statements on record, currently those for fiscal Q3 2026. The 500 largest US-listed companies, and every stock on a HalalScreener watchlist or portfolio, are re-screened daily against the current market cap; every other stock at least once a week. When the company files a new quarterly or annual report with the SEC, it is re-screened from that filing: we check the SEC's filing feed every 15 minutes and the earnings calendar every day. Last screened: Nov 7, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.